

PharmLabs San Diego Certificate of Analysis



Sample **FLO - Mimosa Ice - Hybrid**

Delta9 THC **UI** THCa **ND** Total THC (THCa * 0.877 + THC) **UI** Delta8 THC **88.79%**

Sample ID SD230810-127 (82624)	Matrix Concentrate
Tested for FLO	
Sampled - Received Aug 10, 2023	Reported Aug 14, 2023
Analyses executed CANX	Unit Mass (g) 5.0

Laboratory note: The estimated concentration of the unknown peak in the sample is 10.61% | Currently PharmLabs laboratory can not confirm an unidentified peak in your chromatogram due to interference (only with highly concentrated D8 products) from which we believe to be either (+)δ8-THC or δ9-THC. At this time there are no reference standards available for (+)δ8-THC. (+)δ8-THC is a different compound from the main (-)δ8-THC cannabinoid and, therefore, these two compounds may have different efficacies. Using the most advanced instruments and techniques available, the separation of (+)δ8-THC and δ9-THC is problematic for the scientific community as a whole. PharmLabs believes the unidentified peak to be a combination of (+)δ8-THC and δ9-THC with the majority, if not all, of the concentration being (+)δ8-THC. Total (+/-) D8 Concentration is estimated to be: 88.79%

CANx - Cannabinoids Analysis

Analyzed Aug 14, 2023 | Instrument HPLC-VWD | Method SOP-001
The expanded Uncertainty of the Cannabinoid analysis is approximately **±7.806%** at the 95% Confidence Level

Analyte	LOD mg/g	LOQ mg/g	Result %	Result mg/g	Result mg/Unit	Sample photography
11-Hydroxy-Δ8-Tetrahydrocannabinol (11-Hyd-Δ8-THCV)	0.013	0.041	ND	ND	ND	
Cannabidiol (CBD)	0.006	0.02	ND	ND	ND	
Abnormal Cannabidiol (a-CBDO)	0.013	0.038	ND	ND	ND	
(+/-)-9B-hydroxy-Hexahydrocannabinol (9b-HHC)	0.015	0.045	ND	ND	ND	
11-Hydroxy-Δ8-Tetrahydrocannabinol (11-Hyd-Δ8-THC)	0.015	0.045	ND	ND	ND	
Cannabidiolic Acid (CBDA)	0.033	0.16	ND	ND	ND	
Cannabigerol Acid (CBGA)	0.033	0.16	ND	ND	ND	
Cannabigerol (CBG)	0.048	0.16	ND	ND	ND	
Cannabidiol (CBD)	0.069	0.229	ND	ND	ND	
1(S)-Tetrahydrocannabinol (1(S)-H4-CBD)	0.008	0.026	ND	ND	ND	
1(R)-Tetrahydrocannabinol (1(R)-H4-CBD)	0.016	0.049	ND	ND	ND	
Tetrahydrocannabinol (THCV)	0.049	0.162	ND	ND	ND	
Δ8-tetrahydrocannabinol (Δ8-THCV)	0.012	0.036	ND	ND	ND	
Cannabidiol (CBDH)	0.014	0.042	ND	ND	ND	
Tetrahydrocannabinol (Δ9-THCB)	0.01	0.029	ND	ND	ND	
Cannabinol (CBN)	0.047	0.16	ND	ND	ND	
Cannabidiophorol (CBDP)	0.016	0.049	ND	ND	ND	
exo-THC (exo-THC)	0.005	0.16	ND	ND	ND	
Tetrahydrocannabinol (Δ9-THC)	0.092	0.307	UI	UI	UI	
Δ8-tetrahydrocannabinol (Δ8-THC)	0.044	0.16	88.79	887.90	4439.50	
(6aR,9S)-Δ10-Tetrahydrocannabinol ((6aR,9S)-Δ10)	0.015	0.8	ND	ND	ND	
Hexahydrocannabinol (S Isomer) (9s-HHC)	0.017	0.8	ND	ND	ND	
(6aR,9R)-Δ10-Tetrahydrocannabinol ((6aR,9R)-Δ10)	0.007	0.8	ND	ND	ND	
Hexahydrocannabinol (R Isomer) (9r-HHC)	0.016	0.8	ND	ND	ND	
Tetrahydrocannabinolic Acid (THCA)	0.117	0.389	ND	ND	ND	
Δ9-Tetrahydrocannabinol (Δ9-THCH)	0.02	0.061	ND	ND	ND	
Cannabinol Acetate (CBNO)	0.009	0.027	ND	ND	ND	
Δ9-Tetrahydrocannabinol (Δ9-THCP)	0.017	0.8	ND	ND	ND	
Δ8-Tetrahydrocannabinol (Δ8-THCP)	0.041	0.8	ND	ND	ND	
Cannabicitran (CBT)	0.005	0.16	ND	ND	ND	
Δ8-THC-O-acetate (Δ8-THCO)	0.076	0.8	ND	ND	ND	
9(S)-HHCP (s-HHCP)	0.013	0.041	ND	ND	ND	
Δ9-THC-O-acetate (Δ9-THCO)	0.066	0.8	ND	ND	ND	
9(R)-HHCP (r-HHCP)	0.015	0.045	1.64	16.42	82.10	
9(S)-HHC-O-acetate (s-HHCO)	0.037	0.112	ND	ND	ND	
9(R)-HHC-O-acetate (r-HHCO)	0.031	0.093	ND	ND	ND	
3-octyl-Δ8-Tetrahydrocannabinol (Δ8-THC-C8)	0.021	0.062	ND	ND	ND	
Total THC (THCa * 0.877 + Δ9THC)			UI	UI	UI	
Total THC + Δ8THC + Δ10THC (THCa * 0.877 + Δ9THC + Δ8THC + Δ10THC)			88.79	887.90	4439.50	
Total CBD (CBDA * 0.877 + CBD)			ND	ND	ND	
Total CBG (CBGA * 0.877 + CBG)			ND	ND	ND	
Total HHC (9r-HHC + 9s-HHC)			ND	ND	ND	
Total Cannabinoids Analyzed			90.43	904.32	4521.60	

UI Unidentified
ND Not Detected
N/A Not Applicable
NT Not Reported
LOD Limit of Detection
LOQ Limit of Quantification
<LOQ Detected
>ULOL Above upper limit of linearity
CFU/g Colony Forming Units per 1 gram
TNTC Too Numerous to Count



DCC license: C8-0000098-LIC
DEA license: RP0611043
ISO/IEC 17025:2017 Acc. #85368



Scan the QR code to verify authenticity.

Authorized Signature

Brandon Starr

Brandon Starr, Quality Assurance Manager
Mon, 14 Aug 2023 12:17:08 -0700

PharmLabs San Diego | 3421 Hancock St, Second Floor, San Diego, CA 92110 | 619.356.0898 | ISO/IEC 17025:2017 Acc. #85368



*This report shall not be reproduced except in full, without the written approval of the lab. This report is for informational purposes only and should not be used to diagnose, treat or prevent any disease. Results are only for samples and batches indicated. Results are reported on an "as received" basis, unless indicated otherwise. When a Pass/Fail status is reported, that status is intended to be in accordance with federal, state and local laws which are required for the customer to be in compliance. The measurement of uncertainty is not included in the Pass/Fail evaluation unless explicitly required by federal, state or local laws and has been reported on the certificate of analysis. Measurement of uncertainty is available upon request.